Biliary Cancer Clinical Trials

41 clinical trials for Biliary Cancer across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) — RECRUITING · NA
• To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors — RECRUITING · PHASE1
• A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) — RECRUITING · PHASE1
• PHASE III, RANDOMIZED, OPEN-LABEL, GLOBAL, MULTICENTER STUDY OF RILVEGOSTOMIG OR DURVALUMAB IN COMBINATION WITH CHEMOTHERAPY AS A FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED BILIARY TRACT CANCER (ARTEMIDE-BILIARY02) — RECRUITING · PHASE3
• Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection — RECRUITING
• BEAMION PANTUMOR-1: A PHASE II, MULTICENTRE, MULTICOHORT, OPEN LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZONGERTINIB (BI 1810631) FOR THE TREATMENT OF SELECTED HER2-MUTATED OR OVEREXPRESSED/AMPLIFIED SOLID TUMOURS — RECRUITING · PHASE2
• "A PHASE 3 RANDOMIZED, DOUBLE BLIND STUDY OF PEMBROLIZUMAB PLUS GEMCITABINE/CISPLATIN VERSUS PLACEBO PLUS GEMCITABINE/CISPLATIN AS FIRST-LINE THERAPY IN PARTICIPANTS WITH ADVANCED AND/OR UNRESECTABLE BILIARY TRACT CARCINOMA. — RECRUITING · PHASE3
• A MULTICENTRE, OPEN-LABEL PHASE II STUDY OF NAB-PACLITAXEL IN COMBINATION WITH GEMCITABINE + CISPLATIN AS FIRST LINE TREATMENT IN PATIENTS WITH UNRESECTABLE BILIARY TRACT CANCER — RECRUITING · PHASE2
• Comparing the TDTP-RECIST With RECIST 1.1 and Other Volumetric Evaluation Methods for Assessing the Therapeutic Efficacy of Irregular Malignant Tumors — COMPLETED
• Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of Patients Receiving High-Dose Rate Brachytherapy — COMPLETED · PHASE2
• Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancies — COMPLETED
• Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy — TERMINATED
• My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors — COMPLETED · PHASE2
• A PHASE 1B STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF AMG 193 IN COMBINATION WITH OTHER THERAPIES IN SUBJECTS WITH ADVANCED GASTROINTESTINAL, BILIARY TRACT, OR PANCREATIC CANCERS WITH HOMOZYGOUS MTAP-DELETION (MASTER PROTOCOL) — NOT_YET_RECRUITING · PHASE1
• Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). — TERMINATED · PHASE2
• Neoadjuvant Therapy in Biliary Adenocarcinoma — WITHDRAWN · PHASE1
• Pembrolizumab and GM-CSF in Biliary Cancer — COMPLETED · PHASE2
• Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer — TERMINATED · PHASE2
• A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer — TERMINATED · PHASE1
• A FIRST IN HUMAN, OPEN LABEL, DOSE ESCALATION PHASE I STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY CLINICAL ACTIVITY PROFILE OF SINGLE AGENT RO7119929 (TLR7 AGONIST) ADMINISTERED ORALLY TO PARTICIPANTS WITH UNRESECTABLE ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA, BILIARY TRACT CANCER, OR SOLID TUMORS WITH HEPATIC METASTASES — NOT_YET_RECRUITING · PHASE1
• A PHASE II RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT BEVACIZUMAB IN COMBINATION WITH CISPLATIN PLUS GEMCITABINE IN PATIENTS WITH UNTREATED, ADVANCED BILIARY TRACT CANCER¿ — COMPLETED · PHASE2
• IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread — COMPLETED · PHASE1
• Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma — COMPLETED · PHASE2
• A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism — OTHER · PHASE2
• Tremelimumab With Chemoembolization or Ablation for Liver Cancer — COMPLETED · PHASE1
• PHASE III OPEN-LABEL, MULTI-CENTRE, RANDOMISED STUDY COMPARING NUC-1031 PLUS CISPLATIN TO GEMCITABINE PLUS CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC BILIARY TRACT CANCER — COMPLETED · PHASE3
• Preoperative Nutritional Support in Malnutritional Cancer Patients — COMPLETED · NA
• GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer — OTHER · PHASE2
• Perception Prognosis, Goals of Treatment, and Communication — COMPLETED
• A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers — COMPLETED · PHASE2
• Covered Versus Uncovered SEMS for Palliation of Malignant Biliary Strictures. — COMPLETED · NA
• GTX Regimen for Biliary Cancers — TERMINATED · PHASE2
• Postoperative Oral Nutritional Supplementation After Major Gastrointestinal Surgery — COMPLETED · NA
• A RANDOMIZED PHASE II TRIAL OF MEK INHIBITOR SELUMETINIB (AZD6244) COMBINED CONTINUOUSLY OR SEQUENTIALLY WITH CISPLATIN/GEMCITABINE (CIS/GEM) VERSUS CIS/GEM ALONE IN PATIENTS WITH ADVANCED BILIARY CANCER — COMPLETED · PHASE2
• A PHASE II CLINICAL STUDY OF BBI503 IN ADULT PATIENTS WITH ADVANCED HEPATOBILIARY CANCER — COMPLETED · PHASE2
• A PHASE I TRIAL OF MEK INHIBITOR MEK 162 COMBINED SEQUENTIALLY WITH GEMCITABINE-OXALIPLATIN (GEMOX) IN PATIENTS WITH ADVANCED BILIARY CANCER — NOT_YET_RECRUITING · PHASE1
• Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors — COMPLETED · PHASE1
• Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers — COMPLETED · PHASE1

Refine this search